You are viewing the site in preview mode
Skip to main content
| |
Tofogliflozin group (n = 74)
|
Conventional group (n = 66)
|
Treatment effect (tofogliflozin–conventional treatment) (mean change [95% CI])
|
p value between groups
|
|---|
|
Right baPWV
| | | | |
|
Change from baseline at week 52 (cm/s)
|
− 15.4 (38.1)
|
50.0 (38.3)
|
− 65.4 (–163.1, 32.2)
|
0.19
|
|
Change from baseline at week 104 (cm/s)
|
− 70.6 (31.3) *
|
38.7 (30.2)
|
− 109.3 (–184.3, –34.3)
|
0.005
|
|
Left baPWV
| | | | |
|
Change from baseline at week 52 (cm/s)
|
1.5 (36.9)
|
63.7 (37.3)
|
− 62.2 (–157.1, 32.7)
|
0.20
|
|
Change from baseline at week 104 (cm/s)
|
− 32.6 (30.7)
|
65.8 (29.8)*
|
− 98.3 (–172.6, –24.1)
|
0.010
|
|
Mean baPWV
| | | | |
|
Change from baseline at week 52 (cm/s)
|
− 7.7 (36.7)
|
56.7 (37.0)
|
− 64.4 (–158.8, 29.9)
|
0.18
|
|
Change from baseline at week 104 (cm/s)
|
− 52.5 (30.1)
|
52.2 (29.1)
|
− 104.7 (–177.0, –32.4)
|
0.005
|
- Data are presented as mean (SE) unless stated otherwise. Comparisons of baPWV values during treatment with those at baseline were performed using a one-sample t-test based on the mixed-effects model for repeated measures. *p < 0.05, #p < 0.01, §p < 0.001. Differences in delta change in baPWV from baseline to weeks 52 and 104 between groups at each point (treatment effect) were analyzed with the mixed-effects model for repeated measures. Treatment group, week, interactions between treatment group and week, age, sex, use of insulin at baseline, and baseline baPWV were included as fixed effects
- baPWV brachial-ankle pulse wave velocity
